Gilder Gagnon Howe & Co. LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 114,764 shares of the life sciences company’s stock after acquiring an additional 9,750 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 0.08% of Illumina worth $34,914,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of ILMN. Nuveen Asset Management LLC raised its stake in shares of Illumina by 67,829.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock valued at $832,279,000 after acquiring an additional 2,257,377 shares during the period. Baillie Gifford & Co. grew its holdings in Illumina by 5.0% during the 2nd quarter. Baillie Gifford & Co. now owns 16,775,175 shares of the life sciences company’s stock valued at $6,175,781,000 after purchasing an additional 799,884 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Illumina by 64.8% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,315,437 shares of the life sciences company’s stock valued at $400,182,000 after purchasing an additional 517,226 shares in the last quarter. Nikko Asset Management Americas Inc. grew its holdings in Illumina by 80.9% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 753,124 shares of the life sciences company’s stock valued at $229,115,000 after purchasing an additional 336,821 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in Illumina by 5.2% during the 2nd quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock valued at $2,200,145,000 after purchasing an additional 296,541 shares in the last quarter. 91.76% of the stock is currently owned by institutional investors and hedge funds.
ILMN stock traded up $2.23 during mid-day trading on Tuesday, hitting $328.82. 24,583 shares of the company were exchanged, compared to its average volume of 687,670. The company has a market capitalization of $47.99 billion, a PE ratio of 57.43, a price-to-earnings-growth ratio of 2.41 and a beta of 1.06. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a twelve month low of $263.30 and a twelve month high of $380.76. The firm has a fifty day simple moving average of $308.79 and a 200 day simple moving average of $310.62.
In other news, CFO Sam Samad sold 892 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $320.00, for a total value of $285,440.00. Following the transaction, the chief financial officer now directly owns 3,461 shares in the company, valued at approximately $1,107,520. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Oene Mark Van sold 625 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $304.84, for a total transaction of $190,525.00. Following the completion of the transaction, the senior vice president now owns 14,209 shares in the company, valued at $4,331,471.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,520 shares of company stock valued at $5,038,676. 0.38% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on ILMN shares. Guggenheim started coverage on shares of Illumina in a report on Friday, October 25th. They set a “buy” rating and a $350.00 price target for the company. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Cowen set a $320.00 price target on shares of Illumina and gave the company a “buy” rating in a report on Friday, October 25th. Finally, Argus raised their price target on shares of Illumina from $300.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $333.50.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Sell-Side Analysts
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.